Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

• Status: Completed
• Trial end date: 2010-03-01

Summary

Primary:

• Overall Survival (OS)

Secondary:

• Time to Tumor Progression (TTP)

• Response Rate (RR)

• Improvement of Quality of Life (QoL)

• Safety

• Secondary resection rate

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Doxorubicin; Fluorouracil; Leucovorin; Liposomal doxorubicin; Oxaliplatin